Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEPECA-1: Enfortumab Vedotin Plus Avelumab for Advanced Penile Cancer
NCT07110038Phase 2Recruiting
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- Dec 2025
- Primary completion
- May 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of enfortumab vedotin, avelumab in penile squamous cell carcinoma (PSCC), sponsored by Institut für Klinische Krebsforschung. Started Dec 2025; status: recruiting.
02
Drugs
enfortumab vedotinavelumab
03
Conditions
penile squamous cell carcinoma (PSCC)
Beyond the preview
Go deeper on NCT07110038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07110038.